Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Free Cash Flow (2016 - 2025)

Avanos Medical (AVNS) has disclosed Free Cash Flow for 13 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 67.38% to $21.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.1 million through Dec 2025, down 54.68% year-over-year, with the annual reading at $43.1 million for FY2025, 54.68% down from the prior year.
  • Free Cash Flow hit $21.3 million in Q4 2025 for Avanos Medical, up from $7.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $65.3 million in Q4 2024 to a low of -$12.1 million in Q1 2024.
  • Historically, Free Cash Flow has averaged $16.8 million across 5 years, with a median of $19.5 million in 2024.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 1068.42% in 2021 and later plummeted 237.5% in 2023.
  • Year by year, Free Cash Flow stood at $62.8 million in 2021, then decreased by 29.62% to $44.2 million in 2022, then plummeted by 52.04% to $21.2 million in 2023, then soared by 208.02% to $65.3 million in 2024, then crashed by 67.38% to $21.3 million in 2025.
  • Business Quant data shows Free Cash Flow for AVNS at $21.3 million in Q4 2025, $7.0 million in Q3 2025, and -$4.2 million in Q2 2025.